Nombre del producto:4-(3-bromophenyl)-6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinoline

IUPAC Name:4-(3-bromophenyl)-6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinoline

CAS:543737-10-6
Fórmula molecular:C16H14BrCl2N
Pureza:97%
Número de catálogo:CM105017
Peso molecular:371.1

Unidad de embalaje Stock disponible Precio($) Cantidad
CM105017-25g in stock ȎŢȎ

Sólo para uso en I+D..

Formulario de consulta

   refresh    

Detalles del producto

Núm. De CAS :543737-10-6
Fórmula molecular:C16H14BrCl2N
Punto de fusión:-
Código de sonrisas:CN1CC(C2=CC(Br)=CC=C2)C2=CC(Cl)=CC(Cl)=C2C1
Densidad:
Número de catálogo:CM105017
Peso molecular:371.1
Punto de ebullición:
Nº Mdl:MFCD22683909
Almacenamiento:

Category Infos

Tetrahydroisoquinolines
Tetrahydroisoquinoline is an organic compound with the chemical formula C9H11N. It is classified as a secondary amine, obtained from isoquinoline by hydrogenation. The tetrahydroisoquinoline moiety forms the backbone of several natural, synthetic and semi-synthetic drugs approved for the treatment of cancer, pain, gout and various neurodegenerative diseases.

Column Infos

Quinolines
Quinolines are an important class of biologically active heterocyclic compounds, and their derivatives usually exhibit a variety of biological activities. They can be used as antimalarial drugs and in the preparation of other antimalarial drugs. Other important activities of quinoline derivatives include inhibitory activity against EGFR-TK and antipsychotic activity. Futhermore, quinoline scaffolds are present in various drug molecules, including the antimalarial drugs aablaquine, chloroquine, mefloquine and primaquine, and the antibacterial agents gatifloxacin, levofloxacin, and moxifloxacin.
Tenapanor
FDA has approved XPHOZAH (tenapanor), the first and only phosphate absorption inhibitor, indicated to reduce serum phosphorus in adults with chronic kidney disease (CKD) on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.

XPHOZAH, with its unique blocking mechanism of action, acts locally in the gut to inhibit the sodium hydrogen exchanger 3 (NHE3), reducing phosphate absorption through the paracellular pathway, the primary pathway of phosphate absorption.